Comparative Effectiveness of Metformin vs Sulfonylureas on Exceptional Longevity in Women with Type 2 Diabetes: Target Trial Emulation.

Aladdin H Shadyab, Mark A Espeland, Andrew O Odegaard, JoAnn E Manson, Bernhard Haring, Karen C Johnson, Zhao Chen, Bowei Zhang, Andrea Z LaCroix

Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA. · pubmed

Paper

Abstract

The association of metformin with mortality has been mixed, and no prior study has determined whether metformin initiation is associated with exceptional longevity, defined as survival to ages 90 and older.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that metformin initiation may be associated with exceptional longevity in women with Type 2 diabetes. This study is relevant as it explores the potential impact of a diabetes medication on longevity, which aligns with the investigation of factors that could influence lifespan extension.

Author of this paper? Send a correction.